After-Hours Stock Movers:

The Beauty Health Company (NASDAQ: SKIN) 14.5% HIGHER; reported Q4 EPS of ($0.12), $0.10 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $77.9 million versus the consensus estimate of $71.1 million. The Beauty Health Company sees 2022 revenue of $320-330 million, versus the consensus of $314 million.

Rackspace Technology (NASDAQ: RXT) 13.8% LOWER; reported Q4 EPS of $0.25, $0.01 better than the analyst estimate of $0.24. Revenue for the quarter came in at $777 million versus the consensus estimate of $771.22 million. Rackspace Technology sees Q1 2022 EPS of $0.20-$0.22, versus the consensus of $0.26. Rackspace Technology sees Q1 2022 revenue of $768-778 million, versus the consensus of $789.5 million.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 12.4% LOWER; announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.

Cadence Design Systems (NASDAQ: CDNS) 9.5% HIGHER; reported Q4 EPS of $0.82, $0.06 better than the analyst estimate of $0.76. Revenue for the quarter came in at $773 million versus the consensus estimate of $757.38 million. Cadence Design Systems sees Q1 2022 EPS of $1.00-$1.04, versus the consensus of $0.82. Cadence Design Systems sees Q1 2022 revenue of $850-870 million, versus the consensus of $771.62 million. Cadence Design Systems sees FY2022 EPS of $3.70-$3.80, versus the consensus of $3.56. Cadence Design Systems sees FY2022 revenue of $3.32-3.38 billion, versus the consensus of $3.24 billion.

Teladoc (NYSE: TDOC) 6.9% LOWER; reported Q4 EPS of ($0.07), $0.49 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $554.2 million versus the consensus estimate of $546.6 million. Teladoc sees FY2022 revenue of $2.55-2.65 billion, versus the consensus of $2.57 billion. Teladoc sees Q1 2022 EPS of ($0.60)-($0.50), versus the consensus of ($0.51). Teladoc sees Q1 2022 revenue of $565-571 billion, versus the consensus of $588.94 billion.

Palo Alto Networks (NASDAQ: PANW) 6.5% HIGHER; reported Q2 EPS of $1.74, $0.10 better than the analyst estimate of $1.64. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.28 billion. Palo Alto Networks sees Q3 2022 EPS of $1.65-$1.68, versus the consensus of $1.63. Palo Alto Networks sees Q3 2022 revenue of $1.345-1.365 billion, versus the consensus of $1.35 billion. Palo Alto Networks sees FY2022 EPS of $7.23-$7.30, versus the consensus of $7.23. Palo Alto Networks sees FY2022 revenue of $5.425-5.475 billion, versus the consensus of $5.39 billion.